Last reviewed · How we verify

NCT05053945

Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study

Recruiting now Last updated 29 August 2024
What this trial tests

trial testing Esophagogastroduodenoscopy in Helicobacter Pylori in 260 participants. Currently enrolling.

Timeline
15 May 2020
Primary endpoint
1 December 2025
31 December 2025

Quick facts

Lead sponsorChinese University of Hong Kong
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment260
Start date15 May 2020
Primary completion1 December 2025
Estimated completion31 December 2025
Sites2 locations across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Helicobacter Pylori or Atrophic Gastritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since much is unknown about factors that lead to progression of the pre-neoplastic lesions and cancer. In addition, there is ongoing debate on the optimal surveillance intervals and techniques. To solve these important clinical questions, the establishment of a registry for a longitudinal study is planned.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Esophagogastroduodenoscopy

Trials testing the same drug.

Other recruiting trials for Helicobacter Pylori

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05053945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing